Online citations, reference lists, and bibliographies.
← Back to Search

Pembrolizumab Versus Docetaxel For Previously Treated, PD-L1-positive, Advanced Non-small-cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial

R. Herbst, P. Baas, D. Kim, E. Felip, E. Garon
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. METHODS We did this randomised, open-label, phase 2/3 study at 202 academic medical centres in 24 countries. Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m(2) every 3 weeks. The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of tumour cells. We used a threshold for significance of p<0.00825 (one-sided) for the analysis of overall survival and a threshold of p<0.001 for progression-free survival. This trial is registered at, number NCT01905657. FINDINGS Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients: 345 allocated to pembrolizumab 2 mg/kg, 346 allocated to pembrolizumab 10 mg/kg, and 343 allocated to docetaxel. By Sept 30, 2015, 521 patients had died. In the total population, median overall survival was 10.4 months with pembrolizumab 2 mg/kg, 12.7 months with pembrolizumab 10 mg/kg, and 8.5 months with docetaxel. Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel (hazard ratio [HR] 0.71, 95% CI 0.58-0.88; p=0.0008) and for pembrolizumab 10 mg/kg versus docetaxel (0.61, 0.49-0.75; p<0.0001). Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg, 4.0 months with pembrolizumab 10 mg/kg, and 4.0 months with docetaxel, with no significant difference for pembrolizumab 2 mg/kg versus docetaxel (0.88, 0.74-1.05; p=0.07) or for pembrolizumab 10 mg/kg versus docetaxel (HR 0.79, 95% CI 0.66-0.94; p=0.004). Among patients with at least 50% of tumour cells expressing PD-L1, overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 14.9 months vs 8.2 months; HR 0.54, 95% CI 0.38-0.77; p=0.0002) and with pembrolizumab 10 mg/kg than with docetaxel (17.3 months vs 8.2 months; 0.50, 0.36-0.70; p<0.0001). Likewise, for this patient population, progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 5.0 months vs 4.1 months; HR 0.59, 95% CI 0.44-0.78; p=0.0001) and with pembrolizumab 10 mg/kg than with docetaxel (5.2 months vs 4.1 months; 0.59, 0.45-0.78; p<0.0001). Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel (43 [13%] of 339 patients given 2 mg/kg, 55 [16%] of 343 given 10 mg/kg, and 109 [35%] of 309 given docetaxel). INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection. FUNDING Merck & Co.
This paper references
Pembrolizumab 2 mg / kg Q 3 W for previously treated , PD - L 1 - positive advanced NSCLC [ abstract ]
EA Eisenhauer (2015)
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
K. Schalper (2014)
Ceritinib in ALK-rearranged non-small-cell lung cancer.
A. Shaw (2014)
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
H. Watanabe (2009)
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
P. Jänne (2015)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
Clinical activity and biomarkers of MEDI 4736 , an anti - PD - L 1 antibody , in patients with NSCLC [ abstract ]
V Papadimitrakopoulou (2014)
The PD‐1 pathway in tolerance and autoimmunity
Loise M. Francisco (2010)
Effi cacy , safety and predictive biomarker results from a randomized phase II study comparing MPDL 3280 A vs docetaxel in 2 L / 3 L NSCLC ( POPLAR ) [ abstract ]
AI Spira (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
J. McLaughlin (2016)
Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
V. Papadimitrakopoulou (2015)
Effi cacy , safety and predictive biomarker results from a randomized phase II study comparing MPDL 3280 A vs docetaxel in 2 L / 3 L NSCLC ( POPLAR ) [ abstract ]
LM Francisco (2015)
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion
S. Dzik (2000)
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
J. Brenchley (2006)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
E. Garon (2014)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
A. Patnaik (2015)
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
P. Ascierto (2013)
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
A. Shaw (2013)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Yoshiko Iwai (2002)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
R. Herbst (2014)
B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer: Current Status and Future Direction
S. Gettinger (2014)
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
J. Messina (2012)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Camidge (2014)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
S. Derijcke (2009)
Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.
J. Brahmer (2014)
Comparative analysis of two rates.
O. Miettinen (1985)
Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).
A. Spira (2015)
Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.
Y. He (2015)
Pembrolizumab 2 mg / kg Q 3 W for previously treated , PD - L 1 - positive advanced NSCLC [ abstract ]
Ø Fløtten (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
Pembrolizumab for the treatment of non-small cell lung cancer
S. H. Lim (2016)
The Efficiency of Cox's Likelihood Function for Censored Data
B. Efron (1977)
The B7 family revisited.
R. Greenwald (2005)
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
N. Rizvi (2015)

This paper is referenced by
Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review
Thibaut d'Izarny-Gargas (2020)
Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature
S. Shaheen (2018)
[Immune-related Adverse Events Induced by ICIs in Advanced NSCLC: A Meta-analysis and Systematic Review].
Qiaoxi Qin (2020)
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
C. Kim (2016)
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
Jeroen de Filette (2019)
Functionally impaired follicular helper T cells induce regulatory B cells and CD14+ human leukocyte antigen‐DR − cell differentiation in non‐small cell lung cancer
Liannv Qiu (2018)
A B7‐CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma
Shanbo Zheng (2018)
Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy
D. Wu (2017)
Biomarkers of response to PD-1/PD-L1 inhibition.
Saman Maleki Vareki (2017)
Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib
J. Zugazagoitia (2017)
Fälle aus der Praxis
A. Koenig (2017)
Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
Aaron Simpson (2017)
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
C. Su (2017)
Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors
R. Iacovelli (2017)
Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.
R. Costa (2017)
EGFR TKI combination with immunotherapy in non-small cell lung cancer
M. Ahn (2017)
Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients
P. D. de Goeje (2019)
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
M. Oliva (2019)
Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis
S. Manohar (2019)
[Advances of the Correlation between Driver Gene Status and Immunotherapy 
in Non-small Cell Lung Cancer].
J. Chen (2019)
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
A. Haragan (2019)
The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective
H. M. Guirgis (2018)
Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
A. Pabani (2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
N. Lindeman (2018)
DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
Zhongling Zhu (2018)
Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes
L. Horn (2017)
Advances in evidence‐based medicine for immunotherapy of non‐small cell lung cancer
J. Dong (2018)
Efficacy of icotinib in advanced lung squamous cell carcinoma
Shuai Liang (2018)
Pembrolizumab for the treatment of gastric cancer
Suneel D Kamath (2018)
PD-1/PD-L1 Axis in Lung Cancer
F. Santini (2018)
Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
A. Tun (2019)
Cure in metastatic breast cancer
T. Westphal (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar